Effectiveness of Vaccines and Antiviral Drugs in Preventing Severe and Fatal COVID-19, Hong Kong

被引：11

作者：

Cheung, Yue Yat Harrison ^{[1
]}

Lau, Eric Ho Yin ^{[1
,2
]}

Yin, Guosheng ^{[1
,3
]}

Lin, Yun ^{[1
]}

Cowling, Benjamin J. ^{[1
,2
]}

Lam, Kwok Fai ^{[1
,4
,5
]}

机构：

[1] Univ Hong Kong, Hong Kong, Peoples R China

[2] Hong Kong Sci & Technol Pk, Hong Kong, Peoples R China

[3] Imperial Coll London, London, England

[4] Duke NUS Med Sch, Singapore, Singapore

[5] Univ Hong Kong, Dept Stat & Actuarial Sci, Pokfulam Rd, Hong Kong, Peoples R China

来源：

EMERGING INFECTIOUS DISEASES | 2024年 / 30卷 / 01期

关键词：

NIRMATRELVIR-RITONAVIR; HOSPITAL ADMISSIONS; MORTALITY;

D O I：

10.3201/eid3001.230414

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We compared the effectiveness and interactions of molnupiravir and nirmatrelvir/ritonavir and 2 vaccines, CoronaVac and Comirnaty, in a large population of inpatients with COVID-19 in Hong Kong. Both the oral antiviral drugs and vaccines were associated with lower risks for all-cause mortality and progression to serious/ critical/fatal conditions (study outcomes). No significant interaction effects were observed between the antiviral drugs and vaccinations; their joint effects were additive. If antiviral drugs were prescribed within 5 days of confirmed COVID-19 diagnosis, usage was associated with lower risks for the target outcomes for patients >= 60, but not <60, years of age; no significant clinical benefit was found if prescribed beyond 5 days. Among patients >= 80 years of age, 3-4 doses of Comirnaty vaccine were associated with significantly lower risks for target outcomes. Policies should encourage COVID-19 vaccination, and oral antivirals should be made accessible to infected persons within 5 days of confirmed diagnosis.

引用

页码：70 / 78

页数：9

共 34 条

[1] Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients [J].

Bernal, A. Jayk ;

da Silva, M. M. Gomes ;

Musungaie, D. B. ;

Kovalchuk, E. ;

Gonzalez, A. ;

Delos Reyes, V ;

Martin-Quiros, A. ;

Caraco, Y. ;

Williams-Diaz, A. ;

Brown, M. L. ;

Du, J. ;

Pedley, A. ;

Assaid, C. ;

Strizki, J. ;

Grobler, J. A. ;

Shamsuddin, H. H. ;

Tipping, R. ;

Wan, H. ;

Paschke, A. ;

Butterton, J. R. ;

Johnson, M. G. ;

De Anda, C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (06) :509-520

[2]

Castillo Almeida Natalia E, 2022, NEJM Evid, V1, pEVIDe2100048, DOI 10.1056/EVIDe2100048

[3] Modelling non-linear patterns of time-varying intervention effects on recurrent events in infectious disease prevention studies [J].

Cheung, Yin Bun ;

Ma, Xiangmei ;

Lam, K. F. ;

Yung, Chee Fu ;

Milligan, Paul .

JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2023, 33 (02) :220-233

[4] Estimation of intervention effects using first or multiple episodes in clinical trials: The Andersen-Gill model re-examined [J].

Cheung, Yin Bun ;

Xu, Ying ;

Tan, Sze Huey ;

Cutts, Felicity ;

Milligan, Paul .

STATISTICS IN MEDICINE, 2010, 29 (03) :328-336

[5] Oral antiviral treatment in patients with systemic rheumatic disease at risk for development of severe COVID-19: a case series [J].

Fragoulis, George E. ;

Koutsianas, Christos ;

Fragiadaki, Kalliopi ;

Mariolis, Ilias ;

Panopoulos, Stylianos ;

Tsalapaki, Christina ;

Pappa, Maria ;

Dimitroulas, Theodoros ;

Tektonidou, Maria G. ;

Vassilopoulos, Dimitrios ;

Sfikakis, Petros P. .

ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (10) :1477-1479

[6] Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 [J].

Hammond, Jennifer ;

Leister-Tebbe, Heidi ;

Gardner, Annie ;

Abreu, Paula ;

Bao, Weihang ;

Wisemandle, Wayne ;

Baniecki, MaryLynn ;

Hendrick, Victoria M. ;

Damle, Bharat ;

Simon-Campos, Abraham ;

Pypstra, Rienk ;

Rusnak, James M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (15) :1397-1408

[7] Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial [J].

Han, Bihua ;

Song, Yufei ;

Li, Changgui ;

Yang, Wanqi ;

Ma, Qingxia ;

Jiang, Zhiwei ;

Li, Minjie ;

Lian, Xiaojuan ;

Jiao, Wenbin ;

Wang, Lei ;

Shu, Qun ;

Wu, Zhiwei ;

Zhao, Yuliang ;

Li, Qi ;

Gao, Qiang .

LANCET INFECTIOUS DISEASES, 2021, 21 (12) :1645-1653

[8] Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial [J].

Khoo, Saye H. ;

FitzGerald, Richard ;

Saunders, Geoffrey ;

Middleton, Calley ;

Ahmad, Shazaad ;

Edwards, Christopher J. ;

Hadjiyiannakis, Dennis ;

Walker, Lauren ;

Lyon, Rebecca ;

Shaw, Victoria ;

Mozgunov, Pavel ;

Periselneris, Jimstan ;

Woods, Christie ;

Bullock, Katie ;

Hale, Colin ;

Reynolds, Helen ;

Downs, Nichola ;

Ewings, Sean ;

Buadi, Amanda ;

Cameron, David ;

Edwards, Thomas ;

Knox, Emma ;

Donovan-Banfield, I'ah ;

Greenhalf, William ;

Chiong, Justin ;

Lavelle-Langham, Lara ;

Jacobs, Michael ;

Northey, Josh ;

Painter, Wendy ;

Holman, Wayne ;

Lalloo, David G. ;

Tetlow, Michelle ;

Hiscox, Julian A. ;

Jaki, Thomas ;

Fletcher, Thomas ;

Griffiths, Gareth .

LANCET INFECTIOUS DISEASES, 2023, 23 (02) :183-195

[9] Effectiveness of Second mRNA COVID-19 Booster Vaccine in Immunocompromised Persons and Long-Term Care Facility Residents [J].

Kim, Yoo-Yeon ;

Choe, Young June ;

Kim, Jia ;

Kim, Ryu Kyung ;

Jang, Eun Jung ;

Park, Seon Kyeong ;

Lim, Do-Sang ;

Yi, Seonju ;

Lee, Sangwon ;

Kwon, Geun-Yong ;

Shin, Jee Yeon ;

Choi, Sang-Yoon ;

Jeong, Mi Jin ;

Park, Young-Joon .

EMERGING INFECTIOUS DISEASES, 2022, 28 (11) :2165-2170

[10] Weight, height and body mass index distributions in geographically and ethnically diverse samples of older persons [J].

Launer, KJ ;

Harris, T .

AGE AND AGEING, 1996, 25 (04) :300-306

← 1 2 3 4 →